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Haemophagocytic lymphohistiocytosis (HLH) 
is a condition in which there is pathological, 
unregulated cytokine-mediated stimulation of the 
immune system by functionally defective cyto-
toxic T lymphocytes (CTLs) and natural killer 
(NK) cells.[1-4] Massive amounts of proinflammatory cytokines 
(interleukins 1, 6 and 10, granulocyte macrophage colony stimu-
lating factor, tumour necrosis factor-α and interferon-γ (IFN-γ)) 
released by CTLs result in increased production of non-neoplastic 
lymphocytes and macrophages/histiocytes, along with unremitting 
fever. Thereafter, haemophagocytosis and infiltration of organs by 
cytokine-activated histiocytes result in organomegaly, multiorgan 
dysfunction, life-threatening cytopenias and sepsis.[1]
HLH may be classified as primary/genetic or secondary/acquired 
(Table 1). In genetic HLH, a mutation occurs in one of the proteins 
responsible for intracellular vesicle docking and release of preformed 
proapoptotic granzyme and perforin.[1-4] This in turn reduces the 
ability of CTLs and NK cells to induce apoptosis of antigen-
presenting cells and clonally expanded T lymphocytes. In acquired 
HLH, the exact cause of depressed CTL and NK cell activity is 
less well understood, but it is strongly associated with specific 
viral infections, malignancies and autoimmune disorders.[3,5] It is 
postulated that patients who develop acquired HLH may in fact have 
an underlying (as yet unidentified) genetic predisposition.[6]
Genetic HLH arises in childhood, usually before 1 year of age, but 
there are reports of adults presenting with primary HLH at advanced 
ages.[1,7] As it is due to a genetic mutation, the only chance of cure is 
stem cell transplantation.
Acquired HLH can occur at any age and is treated with combination 
chemotherapy via the HLH-94 trial protocol,[8] along with treatment 
for the suspected trigger (e.g. infection). In cases with a clear trigger 
for acquired HLH (e.g. cytomegalovirus (CMV), HIV), reports of 
complete cure (using immunoglobulins or antiretrovirals) without the 
need for additional chemotherapy have been described.[9-11] Patients 
who are diagnosed with acquired HLH that does not respond to the 
HLH-94 chemotherapy regimen or relapse post-chemotherapy are 
referred for stem cell transplantation.[8]
Much of our knowledge about HLH is derived from Swedish 
paediatric studies in the context of primary HLH, where an incidence 
of 0.12/100 000/year has been estimated.[6] The exact incidence of 
acquired HLH in adults is unknown, although a single-institution 
retrospective analysis of malignancy-associated acquired HLH puts 
the estimate at 0.36/100 000/year.[12]
The diagnostic criteria for HLH are published by the Histiocyte 
Society (http://www.histiocytesociety.org) and require either a 
confirmed molecular diagnosis of genetic mutations known to be 
associated with HLH or the presence of at least 5/8 clinical and 
laboratory criteria. These include:
• prolonged fever
• splenomegaly
• haemophagocytosis (in bone marrow, lymph node or spleen)
• cytopenias
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• fasting hypertriglyceridaemia or hypofibrinogenaemia
• hyperferritinaemia
• low/absent NK cell activity
• elevated soluble CD25 (interleukin-2 receptor) levels.
HLH can mimic many other conditions in its early stages (Table 2). 
It may therefore be underdiagnosed in patients with infection or 
malignancy who present with systemic inflammatory response 
syndrome (SIRS) and acute multiorgan dysfunction.[13,14] A high 
index of suspicion is required to promptly initiate therapy in these 
patients. 
Because awareness of acquired HLH is limited, it typically has 
a high mortality rate (50 - 100%), partly as a reslt of delayed 
diagnosis and treat ment.[14] Recent studies suggest that acquired 
HLH is an under-recognised cause of death in adult intensive 
care units (ICUs).[13,15] Patients usually present with features of SIRS 
(including pyrexia of unknown origin, tachycardia and leuco penia) 
and disseminated intravascular coagulation (DIC), organomegaly 
(specifically splenomegaly with or without hepatomegaly), and may 
additionally exhibit hepatic dysfunction, neurological deficits or septic 
features.[1-3,6,13,15] As not all diagnostic features may be present initially, it 
is essential to monitor patients clinically and biochemically at regular 
intervals. In the early stages, there may be mild manifestations (e.g. skin 
rashes) that resolve spontaneously with subsequent exacerbations.[1]
Importantly, haemophagocytosis is not specific to HLH and can 
be demonstrated in various non-HLH conditions such as post-blood 
transfusion, haemolysis, myelodysplasia/bone marrow failure or 
sepsis.[4,5,13,15] Moreover, haemophagocytosis may not be seen in up 
to 20% of initial bone marrow biopsies[16] and therefore, despite the 
nomenclature, can neither be diagnosed nor excluded solely on the 
basis of presence or absence of haemophagocytosis.[1,15]
We describe five cases of acquired HLH that were diagnosed 
over the course of 5 months (May - September 2013 ) in private 
hospitals in the greater Johannesburg area, South Africa (SA), with 
the aim of raising awareness and increasing the diagnostic pick-
up rate of acquired HLH in adult patients admitted to wards and 
ICUs with multiorgan dysfunction and/or presumed sepsis/SIRS. 
Although only three patients in this series were HIV-positive, the 
high burden of HIV in SA may make this condition more common, 
potentially triggered by coexisting HIV-associated infections and 
malignancies.
All patients were diagnosed with acquired HLH following bone 
marrow aspiration and trephine (BMAT). Clinical information (viz. 
presenting signs and symptoms, temperature trends, organomegaly) 
was obtained either from the bedside at time of BMAT or alternatively 
via communication with the treating physician. All laboratory data 
were accessed on the password-protected Meditech software system 
at Lancet Laboratories.
The clinical and laboratory details of the cases are shown in Table 3. 
Four cases fulfilled the diagnostic criteria for HLH. These include at 
least 5/8 criteria (listed as B1 - B8). No genetic mutational analyses 
were performed (A). Individual results that fit the HLH diagnostic 
criteria are highlighted in bold. Case 2 fulfilled only four criteria, but 
was included in the case series in view of her markedly raised ferritin 
level (24 370 µg/l), hepatomegaly and active haemophagocytosis. 
(Had NK cell activity and/or CD25 assays been available, these may 
have been able to confirm the diagnosis conclusively.) 
All patients were young adults. Cases 2 and 4 tested positive 
for HIV prior to admission and were receiving treatment. During 
admission, a drug-resistance polymerase chain reaction (PCR) 
screen performed on case 2 showed resistance to efavirenz. Case 
1, who was initially HIV-negative according to an enzyme-linked 
immunosorbent assay (ELISA) and p24 antigen assay, seroconverted 
during the course of treatment.
Cases 1 and 2 were diagnosed with diffuse large B-cell lymphoma 
at the time of HLH diagnosis. Neither had undergone chemotherapy 
for lymphoma prior to HLH diagnosis. Case 2 additionally had a 
prior history of high-grade ductal carcinoma. Case 4 had been treated 
for Kaposi’s sarcoma (KS) prior to HLH diagnosis.
All patients had prolonged fever prior to the diagnosis of HLH. 
This feature is consistent among HLH patients and is due to CTL/
NK-mediated hypercytokinaemia rather than to specific infectious 
agents.[1,4] Fevers generally do not resolve despite the use of empiric 
antibiotics.
Splenomegaly was assessed either clinically or radiologically, 
absence of splenomegaly in cases 2 and 4 being confirmed on 
radiological imaging. Splenomegaly is a fairly consistent feature in 
HLH and is due to organ infiltration by activated histiocytes and 
Table 1. Types of HLH* 
Type Subtype Underlying cause/trigger
Genetic/primary Familial Autosomal and X-linked recessive genetic mutations of proteins 
involved in granzyme/perforin-mediated cytolytic function in CTL/NK 
cells: PRF1, UNC13D, STXBP2, RAB27A, STX11, SH2D1A, XIAP
Immune deficiency-associated Chédiak-Higashi syndrome
Griscelli syndrome
X-linked lymphoproliferative syndrome
Acquired/secondary Infection-associated Viral (EBV, HSV, HIV, CMV, B19V)
Bacterial, protozoal, mycobacterial
Malignancy-associated Lymphoma
Leukaemia (particularly T- and NK-cell types)
Solid tumours (rare)
Rheumatic disease-associated 
(macrophage activation syndrome)
SLE, scleroderma, Sjögren’s syndrome, mixed connective tissue 
disorders
HLH = haemophagocytic lymphohistiocytosis; CTL = cytotoxic T-lymphocyte; NK = natural killer; PRF1 = perforin 1 gene; UNC13D = unc-13 homolog D gene; STXBP2 = syntaxin binding 
protein 2 gene; RAB27A = Ras-related protein Rab-27A gene; STX11 = syntaxin 11 gene; SH2D1A = SH2 domain protein-1A gene, XIAP = X-linked inhibitor of apoptosis gene; EBV = Epstein-
Barr virus; HSV = herpes simplex virus; HIV = human immunodeficiency virus; CMV = cytomegalovirus; B19V = parvovirus B19; SLE = systemic lupus erythematosus.
*Adapted from Lehmberg and Ehl,[1] Usmani et al.,[2] Janka and zur Stadt[3] and Arceci.[6]
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lymphocytes.[1,2] Hepatomegaly may similarly develop and commonly 
results in deranged liver enzymes secondary to hepatocyte damage. 
Organomegaly was been shown to be present in 90% of HLH patients 
in a recent Indian case series.[14]
All patients exhibited cytopenias during their stay, although cell 
counts often fluctuated markedly, most commonly following transfusion 
of blood products. As a result, the diagnostic bi-/pancytopenia may not 
be present following blood/platelet transfusion,  a fact to be borne in 
mind when working up a patient for suspected HLH. Importantly, 
underlying neutropenia may be masked if recombinant growth factors 
(e.g. filgrastim ) have recently been administered.
All the patients demonstrated haemophagocytosis in the bone 
marrow, probably because all were at an advanced stage of illness at 
the time of BMAT and their haemophagocytosis was well established. 
The presence of haemophagocytosis signalled the possibility of HLH 
and prompted urgent communication with the treating physicians 
and additional focused laboratory investigations including ferritin, 
fibrinogen and triglyceride levels.
Three patients had raised triglycerides above the diagnostic 3 mM 
level, although the remaining two showed levels closely approaching 
this (2.91 mM and 2.95 mM). Fasting hypertriglyceridaemia is 
seen in ~70% of HLH patients and is thought to be the result of 
cytokine-mediated lipoprotein lipase inhibition.[1,13] Caution should 
be applied when interpreting this parameter in patients known to be 
dyslipidaemic, when a fibrinogen level should preferentially be  tested 
as it is scored under the same diagnostic criterion.
Ferritin and fibrinogen are liver-derived positive acute-phase 
reactants. In the normal inflammatory response, levels of both should 
increase. However, markedly raised ferritin levels in HLH denote 
excessive production by activated histiocytes and possibly release 
Table 2. Mechanisms involved and differential diagnoses of typical clinical and laboratory findings in HLH* 
Pathology Mechanism Differential diagnosis
Cytopenia/s Haemophagocytosis via activated histiocytes Bone marrow hypoplasia/ failure
Bone marrow infiltration (malignant, infective)
Drug-induced myelotoxicity (e.g. HAART, 
chemotherapy)
Sepsis
ITP/TTP
Sequestration (e.g. splenomegaly)
Liver dysfunction Infiltration by activated histiocytes
Hepatocyte damage
Viral hepatitis
Drug-induced hepatitis
Warfarin toxicity
DIC
Sepsis
Fever Pro-inflammatory cytokine release by CTL/NK cells Infection
Neurological deficit/s Demyelination Infections (meningitis, encephalitis)
CVA, space-occupying lesion
Hyperferritinaemia Released from activated histiocytes
? Released from damaged hepatocytes
Ferritin receptor down-regulation
Sepsis
Anaemia of chronic disorders
Iron overload disorders
SLE
Fulminant hepatic failure
Hypertriglyceridaemia Liver infiltration by histiocytes
Decreased levels of lipoprotein lipase
Dyslipidaemia
Diabetes
Nephrotic syndrome
Drugs
Hypofibrinogenaemia Liver infiltration DIC
Liver failure
Hepatomegaly/splenomegaly Organ infiltration by activated histiocytes EPTB
Malignancies (e.g. CML, hepatic metastases)
Infections (e.g. malaria)
Haemolytic states
Extramedullary haematopoiesis
Storage disorders
Cutaneous manifestations
(commonly panniculitis and/
or purpura)
Histiocytic and lymphocytic infiltration Eczema
Erythema nodosum
Panniculitis
Drug-related
Kawasaki disease
HLH = haemophagocytic lymphohistiocytosis; HAART = highly active antiretroviral therapy; ITP = idiopathic thrombocytopenic purpura; TTP = thrombotic thrombocytopenic purpura;  
DIC = disseminated intravascular coagulation; CTL = cytotoxic T-lymphocyte; NK = natural killer; CVA = cerebrovascular accident; SLE = systemic lupus erythematosus;  
EPTB = extrapulmonary tuberculosis; CML = chronic myeloid leukaemia.
*Adapted from Lehmberg and Ehl,[1] Usmani et al.,[2] Jordan et al.,[4] Okabe et al.,[13] Raschke and Garcia-Orr[15] and Morrell et al.[17]
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from hepatocytes in the presence of liver infiltration.[13] Ferritin 
levels were markedly raised in all cases. Though the diagnostic 
threshold is 500 µg/l, reports show that levels >3 000 µg/l should 
raise strong suspicion and initiate prompt investigation for HLH. 
Levels >10 000 µg/l have been shown to be >90% specific for HLH,[1] 
though they may also be associated with fulminant hepatic failure. 
Ferritin is a useful, rapid and relatively cost-effective parameter to 
measure, especially in resource-limited settings.[18] The rate of ferritin 
decline following treatment has been shown to be an important 
prognostic factor for mortality in children.[19] Hypofibrinogenaemia 
Table 3. Case series of patients diagnosed with acquired HLH*
Case 1 Case 2 Case 3 Case 4 Case 5
Age (yrs), gender 32, male 34, female 25, female 47, male 29, female
HLH diagnostic criteria
 A. Molecular diagnosis for HLH-associated 
 genetic mutations
ND ND ND ND ND
B1. Fever Present Present Present Present Present
B2. Splenomegaly Present Absent (mild 
hepatomegaly)
Present Absent Present
B3.  Cytopenia (≥2/3 lineages) Present Present Present Present Present
Anaemia (Hb ≤9 g/dl) 8.2 15.4 7.3 7.7 8.8
Absolute neutropenia (≤1×109/l) 0.71 0.24 0.1† 8.62 16.8
Thrombocytopenia (≤100×109/l) 23 30 49 9 10
 B4. Haemophagocytosis present in BM, 
spleen or lymph node
Present (BM) Present (BM) Present (BM 
and lymph 
node)
Present (BM) Present (BM 
and lymph 
node)
 B5. Fasting hypertriglyceridaemia 
(≥3 mmol/l) and/or 
4.22 2.91 4.20 2.95 7.79
hypofibrinogenaemia (≤1.5 g/l) ND ND 0.94 3.70 0.6
B6. Hyperferritinaemia (≥500 µg/l) 11 427 24 370 19 115 4 072 147 952
B7. Increased soluble CD25 (≥2 400 U/ml) ND ND ND ND ND
B8. Low/absent NK cell activity ND ND ND ND ND
Additional investigations
HIV status Positive Positive Negative Positive Negative
Herpesvirus (EBV, CMV, HHV-8) ND EBNA-positive 
on trephine‡
EBV serology-
negative
CMV-negative
Known 
HHV-8 
positive (KS)
ND
TB Negative Negative Negative Negative ND
Fungal ND ND Positive Positive Negative
Blood cultures Negative Negative Negative CoNS ND
PCR ND Negative for 
P. jiroveci
Negative for 
CMV
ND Negative 
for H1N1, 
influenza A 
and B
Autoimmune screen ND ND Negative for 
CTD
ND Negative for 
c-ANCA, anti-
glomerular 
base
Associated malignancy Yes Yes No Yes No
Likely trigger of HLH Diffuse large 
B-cell lymphoma
? HIV
B-cell lymphoma
EBV
? HIV
Uncertain 
infection
Sepsis
? HIV
? HHV-8
? Autoimmune
Clinical outcome Alive Died Died Died Alive
HLH = haemophagocytic lymphohistiocytosis; ND = not done; Hb = haemoglobin; BM = bone marrow; NK = natural killer; HIV = human immunodeficiency virus; EBV = Epstein-Barr virus; 
CMV = cytomegalovirus; HHV-8 = human herpesvirus-8; EBNA = Epstein-Barr virus nuclear antigen 1; KS = Kaposi’s sarcoma; TB = tuberculosis; CoNS = coagulase-negative Staphylococcus; 
PCR = polymerase chain reaction; CTD = connective tissue disease; c-ANCA = cytoplasmic anti-neutrophil cytoplasmic antibody.
*Individual results that fit the HLH diagnostic criteria are highlighted in bold.
†Total white cell count. A valid differential count could not be performed because there were too few leucocytes.
‡Determined by in situ hybridisation.
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(in the absence of liver failure or laboratory features of DIC) 
suggests immune dysregulation and should arouse suspicion of HLH, 
especially if associated with splenomegaly. Importantly, the presence 
of DIC does not preclude HLH as it is common in these patients.[15] 
Fibrinogen levels were measured in cases 3 - 5 only (as part of DIC 
screening) with cases 3 and 5 showing diagnostically low levels.
Neither NK cell activity nor CD25 assays were performed, as neither 
assay is widely available locally. Owing to technical aspects of the 
assays, if available, and delay in obtaining results, it is recommended 
that blood be taken at the earliest possible opportunity during work-up 
for suspected HLH. For all the patients in this series, NK cell or CD25 
assays may have been of limited use owing to the advanced stage of 
disease at time of BMAT. NK cell and CD25 assays may, however, assist 
in raising the diagnostic pickup rate of HLH, especially if patients do 
not meet the criteria for the remaining parameters.
Additional investigations were performed on all patients in the 
search for a trigger for suspected sepsis/SIRS before the diagnosis 
of HLH was made. These investigations varied between treating 
physicians and were probably focused according to individual clinical 
symptoms and comorbidities. The search for infective triggers involved 
testing for herpesviruses, tuberculosis (TB), aerobic micro-organisms 
and fungi. Members of the herpesvirus family coincidentally are the 
most frequent triggers of viral-associated HLH.[5,6,20] These include 
Epstein-Barr virus (EBV), the reactivation of which has been implicated 
the most in viral-associated HLH,[21] CMV and human herpesvirus 8 
(HHV-8). EBV was detected by in situ hybridisation of the trephine in 
case 2. EBV serology was negative in case 3. 
TB investigations were carried out on peripheral blood (case 1), 
ascitic fluid (adenosine deaminase measurement only, case 4), sputum 
(cases 2 and 3), urine (case 2), bone marrow aspirate (cases 1 and 
4). All yielded negative results. Cases 3 and 4 yielded positive fungal 
results on peripheral blood cultures. Case 3 had a severe neutropenia 
of 0.04×109/l at the time of fungal culture sampling, while case 4 had 
normal absolute neutrophil and lymphocyte counts of 5.19×109/l 
and 3.07×109/l, respectively. It is therefore likely that the fungaemia 
identified in case 3 resulted from HLH-related severe neutropenia 
and was considered unlikely as an initial trigger. Blood cultures from 
case 4 yielded a coagulase-negative staphylococcal infection while 
negative cultures were obtained from the other cases. Cultures of 
catheter tips, urine and skin swabs were all negative.
PCR assays for potential HLH triggers, Pneumocystis jiroveci, 
CMV and influenza were performed on cases 2, 3 and 5, respectively 
and were all negative. CMV is an infrequent trigger of HLH, but has 
been shown to respond well to intravenous immunoglobulin thereby 
avoiding the need for chemotherapy.[21]
A connective tissue disease screen was performed on case 3, as 
she presented with a history of erythema nodosum that responded 
well to steroids. Biopsy of the lesion revealed septal panniculitis. 
She subsequently deteriorated clinically upon withdrawal of steroid 
therapy. Results of the connective tissue disease screen were negative. 
Cytoplasmic anti-neutrophil cytoplasmic antibody and glomerular 
membrane base antibody screens were performed on case 5 as 
she presented with features of vasculitis and malar rash at time of 
admission. The results were also negative.
Three of the five cases had a malignancy at the time of 
diagnosis. In malignancy-associated HLH, HLH can precede the 
malignancy diagnosis, occur after diagnosis or manifest during 
chemo therapy. It is largely associated with T-/NK cell lymphomas or 
leukaemias.[2,5] However, an association with large B-cell lymphomas 
has been described.[22] It has been postulated that HLH is triggered by 
release of IFN-γ and CD25 from neoplastic cells, causing significant 
macrophage activation.[5] 
HIV has been listed as a trigger of HLH in the literature, but the 
exact mechanism/s by which this occurs is not yet understood.[9,23] 
HLH is common during the period of seroconversion, though it 
may occur at any time.[9] There is a paucity of information regarding 
optimal treatment of HIV-positive patients presenting with HLH. A 
French retrospective study of 58 HIV-positive patients showed that 
reactive haemophagocytic syndrome was diagnosed in patients with 
a median CD4+ count of 91 cells/µl, with 35% of patients having viral 
loads (VLs) of <50 copies/ml at diagnosis.[23] Single case reports from 
Japan reported cures with antiretroviral therapy alone.[9,10] Case 3 had 
a CD4+ count of 50 cells/µl with a VL of 459 444 copies/ml. Case 4 
had CD4+ count of 586 cells/µl with a VL of <20 copies/ml, but he 
had previously been treated for KS, according to clinical information 
provided. HHV-8 has been shown to act as an HLH trigger in HIV-
positive cases in a limited case series. However, the median CD4+ 
counts of the patients was significantly lower (200 cells/µl).[20] Case 1 
was HIV-negative on ELISA and p24 antigen-negative at admission. 
Recent repeat HIV testing revealed that he is HIV-positive with a 
CD4+ count of 371 cells/µl and a VL of 104 copies/ml. Hence, HLH 
may have been triggered by either seroconversion or malignancy.
The treating physicians were contacted immediately after the 
diagnosis of HLH was made and were advised to urgently seek 
treatment advice from a clinical haematologist. Unfortunately, all 
patients were at advanced stages of disease at the time of BMAT and 
cases 2 - 4 succumbed to their illness shortly thereafter. Cases 1 and 
5 received appropriate treatment after diagnosis and were alive at 
time of writing.
The normal immune response to antigenic stimuli (viz. viruses, 
bacteria or malignancies) involves the clonal expansion of specific 
CD4- and CD8-positive T-lymphocytes along with the generation 
of cytokines to recruit macrophages to the site of concern. A defect 
in CTL and NK cell-directed apoptosis (via perforin and granzyme) 
of these activated clonal lymphocytes once the stimulus has been 
removed forms the common pathway of familial and acquired 
HLH. Defective apoptosis results in increasing production of pro-
inflammatory cytokines, resulting in a catastrophic cascade of events, 
terminating in multiorgan failure and death. HLH is considered 
to be rare, and much of what is known in the literature is found 
in paediatric journals concerned with the familial form. As such, 
acquired HLH remains a largely unknown entity in adult medicine 
and its diagnosis is frequently missed in ICU settings.
This limited case series suggests that adult acquired HLH may be a 
common pathology in acute care settings, where it may masquerade 
as sepsis or SIRS. Unless it is diagnosed early and appropriate treat-
ment is instituted, the mortality rate is high. Much of the information 
regarding chemo-/immunotherapy has been gleaned from the HLH-
94 protocol where children under 16 years of age were administered 
etoposide, dexamethasone and cyclosporine (while awaiting a stem 
cell transplant if diagnosed with familial HLH or relapsing/non-
responding secondary HLH). A 5-year survival rate of 54% (standard 
deviation ±6) was achieved with the HLH-94 trial – a remarkable 
improve ment when previously the mortality rate approached 100%.[8] 
Given the complex nature of the condition, treatment requires the 
expertise of a clinical haematologist or medical oncologist well versed 
in the complexity and challenges of HLH if cure is to be achieved. The 
concept of using chemotherapy to treat a non-neoplastic condition 
may seem drastic to medical personnel not familiar with the disease, 
but its use is essential to induce apoptosis in the defective NK cells 
and CTLs and quell the cytokine storm.
Establishing a diagnosis of HLH may be difficult in the early 
stages of disease, as most diagnostic parameters (apart from the 
gene-specific assays) are in themselves fairly nonspecific. In the 
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case of oncology patients or those with HIV, the list of differential 
pathologies is considerable. Only when seen together does a picture 
of immune hyperstimulation and resulting multiorgan failure emerge.
Possible methods to increase the diagnostic pick-up rate of 
acquired HLH include auto-flagging of haematological results that 
exceed upper limits for certain diagnostic criteria (e.g. raised ferritin 
in the presence of low fibrinogen levels). Alternatively, a standard 
algorithm for work-up of cases of suspected sepsis with unresolving 
pyrexia and organomegaly could be instituted in acute care settings. 
Though not part of the HLH diagnostic criteria, the absence of liver 
dysfunction in a suspected HLH patient should prompt treating 
physicians to consider alternative diagnoses.
It is important to note that in this case series, patients received 
a diagnosis of HLH only after BMATs were performed to further 
investigate cytopenias or possible septic foci. It is not known how many 
HLH cases may have gone undiagnosed in patients who revealed no 
haemophagocytosis on aspirates/trephines. Reports on the role of flow 
cytometry in diagnosing HLH on bone marrow aspirates show promise 
and may assist in increasing the pick-up rate.[1,24] It is hoped that this 
case series raises awareness of adult acquired HLH in intensivists, 
oncologists, physicians and infectious disease experts.
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